Pulmonx Co. (NASDAQ:LUNG) Shares Purchased by Cubist Systematic Strategies LLC

Cubist Systematic Strategies LLC increased its holdings in shares of Pulmonx Co. (NASDAQ:LUNG) by 141.6% in the second quarter, Holdings Channel reports. The firm owned 109,105 shares of the company’s stock after buying an additional 63,945 shares during the quarter. Cubist Systematic Strategies LLC’s holdings in Pulmonx were worth $692,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently bought and sold shares of the business. Point72 Asia Singapore Pte. Ltd. purchased a new position in Pulmonx during the 2nd quarter worth $37,000. Allspring Global Investments Holdings LLC raised its position in Pulmonx by 609.7% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 8,516 shares of the company’s stock worth $79,000 after buying an additional 7,316 shares during the last quarter. EntryPoint Capital LLC purchased a new position in Pulmonx during the 1st quarter worth $102,000. Hsbc Holdings PLC purchased a new position in Pulmonx during the 2nd quarter worth $93,000. Finally, Mackenzie Financial Corp purchased a new position in Pulmonx during the 2nd quarter worth $102,000. Institutional investors and hedge funds own 91.04% of the company’s stock.

Pulmonx Stock Performance

Shares of LUNG opened at $6.67 on Friday. The company has a 50-day simple moving average of $7.20 and a 200-day simple moving average of $7.45. The company has a quick ratio of 7.92, a current ratio of 8.97 and a debt-to-equity ratio of 0.37. The company has a market capitalization of $261.13 million, a PE ratio of -4.45 and a beta of 0.64. Pulmonx Co. has a 52-week low of $5.46 and a 52-week high of $14.84.

Pulmonx (NASDAQ:LUNG) last posted its earnings results on Wednesday, July 31st. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.02. Pulmonx had a negative net margin of 75.56% and a negative return on equity of 50.79%. The firm had revenue of $20.78 million during the quarter, compared to the consensus estimate of $20.23 million. Equities research analysts predict that Pulmonx Co. will post -1.64 earnings per share for the current fiscal year.

Insider Buying and Selling at Pulmonx

In other Pulmonx news, Director Glendon E. French III sold 20,000 shares of the firm’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $8.09, for a total transaction of $161,800.00. Following the completion of the transaction, the director now directly owns 1,111,974 shares in the company, valued at approximately $8,995,869.66. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Pulmonx news, Director Glendon E. French III sold 20,000 shares of the firm’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $8.09, for a total transaction of $161,800.00. Following the sale, the director now directly owns 1,111,974 shares of the company’s stock, valued at $8,995,869.66. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Steven S. Williamson purchased 14,245 shares of the firm’s stock in a transaction on Tuesday, August 20th. The shares were purchased at an average cost of $6.84 per share, for a total transaction of $97,435.80. Following the completion of the purchase, the chief executive officer now directly owns 219,531 shares in the company, valued at $1,501,592.04. The trade was a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders sold 30,351 shares of company stock worth $231,094. 5.70% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Canaccord Genuity Group upped their price objective on shares of Pulmonx from $15.00 to $16.00 and gave the stock a “buy” rating in a research report on Thursday, August 1st. Wells Fargo & Company cut their price target on shares of Pulmonx from $14.00 to $10.00 and set an “equal weight” rating for the company in a report on Thursday, August 1st. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $14.83.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.